China drugmaker begins trial production of AstraZeneca COVID-19 vaccine
SHENZHEN -- A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
- Hong Kong's economy grows steadily in Q1, hitting 5-quarter high
- Taiyuan officials draw lessons from April 30 explosion
- Xi's diplomacy injects certainty, stability into turbulent world
- Vibrant snapshots of China during Labor Day holiday
- Revised infectious disease law strengthens public health system
- Port in Macao sets new records on 1st day of May Day holiday
